cpfe diagnosis and treatment

Some potential risks do exist in the treatment of CPFE (combination pulmonary fibrosis pulmonary emphysema). These risks arise mainly from the side effects of drugs, the interaction of drugs and individual differences among patients. These potential risks are described in detail below: Long-term use, such as sulfur tablets, thiphonone capsules, may lead to damage to liver and kidney function, bone marrow inhibition, gastrointestinal reaction (e.g., nausea, vomiting, diarrhoea, etc.) and allergies such as rash and itch. It can also give rise to adverse effects such as light allergies, lack of power and dizziness. bronchial expansion agents: Such drugs may result in adverse reactions such as increased heart rate, increased blood pressure, headaches, tremors, etc. Long-term use may also lead to drug resistance, leading to a decrease in drug efficacy. Other drugs such as sugar cortex hormones may cause side effects such as osteoporosis, increased blood sugar, increased blood pressure and digestive ulcer. Antibiotics can cause intestinal group disorders, damage to liver and kidney functions, etc. Drug metabolic interference: Certain drugs may interfere with the metabolic process of other drugs, resulting in their accumulation or excretion in the body, thereby affecting efficacy and safety. (b) When two or more drugs are used at the same time, they may reinforce or diminish each other ‘ s efficacy, leading to poor treatment or excessive response. Age and sex: There may be differences in the response of patients of different ages and gender to drugs. For example, older persons have a relatively poor liver and kidney function, reduced metabolic and excretion capacity for drugs, and are vulnerable to drug accumulation and adverse reactions. Genetic and physical: Disparities in the patient ‘ s genetic background and body may also affect the efficacy and safety of the drug. For example, certain patients may be allergic to or intolerant of certain drugs. Basic diseases: CPFE patients may suffer from other basic diseases at the same time (e.g. hypertension, diabetes, etc.), which may affect the choice and use of medicines. For example, high blood pressure patients may need to be cautious when using certain bronchial expansion agents to avoid further increase in blood pressure. Other potential risks Drug dependence and drug resistance: Long-term use of certain drugs may result in dependence or resistance of patients, thus affecting treatment effectiveness. Financial burden: Drug treatment of CPFE may require long-term use of drugs, placing a certain financial burden on patients. 5. Medically prescribed medicines: Patients shall strictly comply with medically prescribed medicines and may not alter their doses or stop them at will. Medical consultations should be conducted in a timely manner in the event of any discomfort or unusual reaction during the course of the treatment. (b) Periodical examination of liver and kidney function, blood protocol, etc. to assess the effects of the drug on the patient ‘ s body. Drug Adjustment: Timely adjustment of drug types and doses in response to changes in the patient ‘ s condition, drug efficacy and adverse effects. Lifestyle interventions: Lifestyle interventions such as cessation of smoking and protection from environmental exposure are also one of the important measures to treat CPFE. These measures help to reduce the disease, improve the quality of life and reduce the potential risks of drug treatment. In the light of the above, there are a number of potential risks to the treatment of CPFE. Patients should be fully aware of these risks and, under the guidance of a doctor, use them rationally, regularly monitor and adjust treatment programmes. At the same time, lifestyle interventions are an integral part of the treatment of CPFE.